Mali’s innovative use of the R21/Matrix-M vaccine in Kayes and Mopti

Mali is reaching a pivotal moment in its fight against malaria. By implementing the WHO-endorsed R21/Matrix-M vaccine, the regions of Kayes and Mopti are pioneering a fresh immunization approach. This medical shield, combining seasonal delivery with careful monitoring, is now safeguarding thousands of Malian children.

Demonstrating its commitment to public health, Mali has integrated the R21/Matrix-M malaria vaccine into its Expanded Programme on Immunization (EPI). Supported by international partners like Gavi, UNICEF, and the WHO, this rollout focuses on 19 priority districts across five regions, with Kayes and Mopti leading the way through advanced methodology.

The “hybrid” strategy: A precision health tool

Moving beyond traditional vaccination methods, Mali has adopted a hybrid model. This technique blends two administration styles to ensure maximum effectiveness:

1. Age-specific dosing: Establishing foundational immunity in infants from an early age.
2. Seasonal administration: Timing doses just before the peak transmission period (the rainy season) to ensure protection is highest when mosquito populations surge.

Kayes and Mopti: Monitoring priority districts

The selection of Kayes and Mopti as pilot areas is based on urgent epidemiological data. These locations are among the 19 high-priority districts testing the durability and resilience of the national health infrastructure.

In Mopti, despite logistical hurdles, effective collaboration between health services and global partners has ensured a steady supply chain. Meanwhile, in Kayes, strong community engagement is key to ensuring that vital booster shots for the R21 vaccine are delivered on schedule.

A multi-layered defense system

Health officials emphasize that while the R21/Matrix-M vaccine is a powerful new tool, it does not replace existing prevention methods.

• Insecticide-treated nets: These remain vital for nighttime protection against bites.
• Seasonal Malaria Chemoprevention (SMC): The vaccine works in synergy with preventive medications already being distributed to children.

Projected impact on child survival

The primary goal of this vaccine introduction is to significantly lower malaria-related deaths among children under five, who represent the most vulnerable age group. The results from this phase in the districts of Kayes and Mopti will determine the future expansion of the program across the entire territory of Mali.